Hensin Tsao, MD, PhD, is the Clinical Director of the Mass General Melanoma & Pigmented Lesion Center, Director of the Melanoma Genetics Program, and a member of the Massachusetts General Hospital Cancer Center's Center for Melanoma.
BiographyHensin Tsao, MD, PhD is a board-certified dermatologist and Associate Professor of Dermatology at Harvard Medical School. Presently, he is Director of the Melanoma and Pigmented Lesion Center, the Melanoma Genetics Program, and the Skin Cancer Genetics Laboratory in the Wellman Center for Photomedicine, all of which are at the Massachusetts General Hospital. Beyond patient care, he dedicates much of his time to melanoma research and the education of medical students, dermatology residents, and fellows.
Hensin Tsao, MD, PhD received his undergraduate degree from Brown University where he graduated magna cum laude and Phi Beta Kappa. Later, he graduated Alpha Omega Alpha from the Columbia University College of Physicians and Surgeons with a MD degree and received his PhD from Columbia University Graduate School of Arts of Sciences. Dr. Tsao completed one year of clinical training in internal medicine and three years of dermatology residency, including one-year Melanoma Fellowship in the Harvard-affliated hospitals. He concluded his training with a postdoctoral fellowship in the Division of Oncology at Massachusetts General Hospital.
Dr. Tsao supervises an active cancer genetics laboratory and is the author of more than 100 scholarly articles, reiews, abstracts, textbook chapters, and online media texts. He has also delivered more than 100 lectures on melanoma, genetics, and skin disease throughout the world. To learn more visit The Wellman Center for Photomedicine.
Hensin Tsao, MD, Director of Mass General's Melanoma and Pigmented Lesion Center explains how family history, genetic risks and personal health history can all affect your risk of melanoma, and what steps you should take to detect it at an early, treatable stage.
Browse the latest local and national news articles featuring stories from basic research to innovative breakthroughs in cosmetic dermatology.
A major international study has identified a novel gene mutation that appears to increase the risk of both inherited and sporadic cases of malignant melanoma, the most deadly form of skin cancer. The identified mutation occurs in the gene encoding MITF, a transcription factor that induces the production of several important proteins in melanocytes, the cells in which melanoma originates.